AGTC is developing novel therapeutics for patients with unmet medical needs utilizing the non-pathogenic adeno-associated virus to deliver therapeutic genes. AGTC's lead program is a treatment for Alpha One Anti-trypsin Deficiency, the most common hereditary disease in the U.S.. AGTC is also collaborating with Genzyme to develop, manufacture and market a gene therapy product to treat Wet Age-Related Macular Degeneration. The Company is located in Gainesville, Florida in the University of Florida's Sid Martin Biotechnology Development Incubator.

AGTC is developing novel therapeutics for patients with unmet medical needs utilizing the non-pathogenic adeno-associated virus to deliver therapeutic genes. AGTC's lead program is a treatment for Alpha One Anti-trypsin Deficiency, the most common hereditary disease in the U.S.. AGTC is also collaborating with Genzyme to develop, manufacture and market a gene therapy product to treat Wet Age-Related Macular Degeneration. The Company is located in Gainesville, Florida in the University of Florida's Sid Martin Biotechnology Development Incubator.

AkaRx, Inc. is a biopharmaceutical company headquartered in Paramus, New Jersey, and dedicated to the development of novel therapeutic treatments that address unmet medical needs and provide significant benefits over currently available therapies. AkaRx, Inc. was formed in 2005 as a spin out of the merger of Yamanouchi Pharmaceutical Co., Ltd and Fujisawa Healthcare, Inc. The company's lead product, AKR-501, is for the treatment of platelet disorders of diverse etiologies.

Alvine Pharmaceuticals, Inc., is a Palo Alto-based biopharmaceutical company dedicated to developing and commercializing therapeutics for the treatment of celiac sprue, a gluten-induced autoimmune disease for which no drug therapy is currently available. Alvine's lead molecule, ALV001, is an oral protease designed to be consumed with food to destroy gluten in the stomach before it can exert a toxic effect in the intestine. Celiac sprue is believed to affect as many as two million people in the United States alone, many of whom have suffered the symptoms of the disease but have not yet been diagnosed.

AlgoRx Pharmaceuticals was a startup biopharmaceutical company established to license in and develop novel therapeutic approaches to address the unmet need for better management of pain. AlgoRx merged with Corgentech in December, 2005 to form Anesiva.

Founded in 2007 and headquartered in Rockville, MD, Amplimmune is focused on developing novel biologics that are key co-stimulatory/co-inhibitory molecules that rebalance the immune system and are intended for treating cancer, autoimmune disease, infectious disease, and transplantation. With its strong product-based focus, Amplimmune is rapidly advancing two lead molecules toward clinical development: AMP-224 in the area of cancer and infectious disease; and AMP-110 for autoimmune diseases. Working closely with its founders at Johns Hopkins University and other collaborators, Amplimmune is expanding its technology base in the area of immune co-stimulatory/co-inhibitory molecules and has assembled a large foundation of reagents, models, know-how, and intellectual property to further develop its product pipeline as well as to discover novel biomarkers, ligands, and receptors.

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has three drug candidates in development for multiple pain-related indications. A New Drug Application (NDA) has been submitted for the most advanced product, Zingo™. The second product in the pipeline, 4975, has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. A third product, 1207, is currently being evaluated in a Phase 1 clinical trial as a topical local anesthetic. Anesiva is based in South San Francisco, California.

APT Pharmaceuticals, Inc., located in Burlingame, CA, is a drug development company focused on developing well-characterized drugs for serious lung diseases.

ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA began operations in 2005 and is headquartered in Denver, Colorado.

Arcion Therapeutics Inc. is a clinical stage biotechnology company focused on the development of new, targeted treatments for severe pain. Arcion has a pipeline of products being developed for the treatment of painful diabetic neuropathy, post-herpetic neuralgia and other forms of moderate and severe pain. The company is located in Baltimore, Maryland.

Aspreva is an emerging global pharmaceutical company focused on identifying, developing and, upon regulatory approval, commercializing new indications for approved drugs and late stage drug candidates for patients living with less common diseases. Their lead program, through an innovative partnership with Hoffmann - La Roche, Inc., is focused on the development of CellCept in autoimmune diseases. Aspreva is headquartered in Victoria, British Columbia with offices in New Jersey, the United Kingdom and Switzerland.

BioMimetic Therapeutics, Inc. is developing and commercializing bio-active drug-device combination products for the healing of musculoskeletal injuries and disease, including periodontal, orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21SD, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of its platform technology in this indication. Additionally, the Company has clinical trials ongoing for orthopedic bone healing indications. The Company's product and product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration. BioMimetic is headquartered in Franklin, TN.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms — GVAX(R) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapy for pancreatic cancer and leukemia, and a Phase I trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for.

COR was funded to develop and commercialize innovative pharmaceutical products for the treatment and prevention of severe cardiovascular diseases, such as unstable angina and acute ischemic coronary syndrome, and stroke. Cor went public in 1991 and was acquired by Millenium in 2001.

Corixa was formed in 1994 to develop vaccines and therapeutic products for cancer and infectious diseases, based on novel approaches to immunization, stimulation, and culture of cytotoxic T cells and T helper cells.

Coulter Pharmaceutical developed monoclonal antibody-based anti-cancer drugs that hone in on tumor cells without devastating surrounding healthy tissues. The company's flagship product was the first anti-B1 antibody-based therapy for the treatment of non-Hodgkin's lymphoma. The company merged with Corixa in December 2000.

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIND (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides. The Cubist product pipeline includes their lipopeptide program and their natural products screening program. Cubist is headquartered in Lexington, MA.

Drais Pharmaceuticals, Inc. is an ethical pharmaceutical company headquartered in Bridgewater, New Jersey, and dedicated to the development of novel therapeutic treatments that address unmet medical needs and provide significant benefits over currently available therapies.

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent allergies, infectious diseases, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavaxos TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax is based in Berkeley, CA.

Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger's pipeline includes preclinical new chemical entities from internal discovery efforts as well repurposed clinical and approved drugs shown to possess novel antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.

Inspire Pharmaceuticals discovers and develops breakthrough products to treat diseases involving impaired hydration of the body's mucosal surfaces such as Chronic Bronchitis and Dry Eye Disease. These products are targeted at disorders with high unmet medical needs representing large, near-term market opportunities. Each product in Inspire's pipeline, whether in clinical or preclinical development, presents a novel approach to the treatment of disease, one which is expected to provide significant medical benefit and improvement in patient quality of life. Inspiration Pharmaceuticals is located in Durham, NC.

VIntarcia Therapeutics, Inc., a privately held biopharmaceutical company, applies a targeted approach to the acquisition, development and commercialization of therapeutic products. Intarciaos lead programs include an implant to deliver omega interferon for the treatment of hepatitis C and multiple sclerosis. The company is also working on an implant for diabetes. Intarcia is based in Emeryville, CA.

KAI Pharmaceuticals is a privately held, venture-backed drug discovery and development company with preclinical and clinical programs in acute cardiovascular and other diseases representing unmet medical needs. The company has applied its core expertise in the biology of protein kinase C (PKC) to develop highly potent and selective inhibitors and activators for each of the PKC isozymes for the treatment of a broad array of human diseases. KAI has received Fast-Track designation from the FDA for its lead compound, KAI-9803, which has recently completed a Phase I/II clinical trial to assess safety and efficacy in treating reperfusion injury in acute myocardial infarction. KAI is based in South San Francisco, California.

Lycera Corp. is focused on the discovery and development of small-molecule therapies for the treatment of immunologic diseases, including psoriasis, rheumatoid arthritis, inflammatory bowel disease and transplant rejection. Lycera is advancing drug candidates that target two totally novel therapeutic pathways aimed at selectively downregulating chronically activated immune cells without broad immune suppression.

Founded in 2000, MacroGenics is a private, biotechnology company headquartered in Rockville, Maryland that focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company's proprietary Fc engineering technology offers ways of improving antibody function, such as enhancing its ability to eliminate cancer cells, cells that contribute to autoimmune disorders, or those infected with certain pathogens. The company is developing first-in-class product candidates from its autoimmunity, oncology and infectious disease portfolios.

Metabasis Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs to address some of the world's most widespread and costly chronic diseases. The Company has established a pipeline that includes clinical stage and preclinical product candidates targeting major diseases with significant unmet medical needs. Targeted diseases include metabolic diseases such as diabetes, hyperlipidemia and obesity as well as liver diseases such as hepatitis and primary liver cancer. Metabasis has developed several proprietary technologies for use in discovering and optimizing drugs, including the NuMimetic(TM) and HepDirect(R) technologies. Metabasis is continuing to identify and develop new product candidates using its proprietary technologies and expertise.

Myogen, a University of Colorado Medical Center based company, developed therapeutics for the treatment of heart disease. The Company's strategy was to leverage its molecular and clinical expertise in heart muscle disease to discover new therapeutic targets for drug development, and develop and add value to in-licensed products. Myogen was acquired by Gilead Pharmaceuticals in December, 2006.

Nereus Pharmaceuticals pursues untapped sources of chemical diversity to discover and develop novel therapeutics. With expertise in marine microbiology and integrated technologies to identify and synthesize novel biologically active compounds, the Companyos two oncology drug candidates are in Phase I clinical trials. NPI-2358, a tumor vascular disrupting agent, is being evaluated for solid tumors, and proteasome inhibitor NPI-0052 is being developed for solid tumors, lymphomas and multiple myeloma. Nereuso discovery portfolio also includes additional drug candidates for oncology, as well as infectious diseases and inflammation. The company is located in San Diego, CA.

Neurex was a biotechnology company engaged in the discovery and development of new therapeutics which modulate the activities of the central and peripheral nervous system by regulating nerve cell communication. SNX-111 was identified as the first development candidate arising from Neurex's technology. The company was acquired by Elan Corporation in April, 1998.

NovaCardia,based in San Diego, CA, is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardiaos lead product, KW-3902, is in-licensed from Kyowa Hakko and is an adenosine A1 antagonist for the treatment of congestive heart failure.

Ocera Therapeutics Inc. founded in January 2005, is a privately held, clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for gastrointestinal and liver diseases.

On Demand Therapeutics is developing implantable devices to enable on demand release of drugs to the back of the eye, controlled by the ophthalmologist, leveraging existing equipment and skills

QuatRx Pharmaceuticals is a pharmaceutical company focused on the discovery, licensing, development and commercialization of compounds in the endocrine, metabolic and cardiovascular therapeutic areas.

Salmedix was a San Diego, CA, start-up biotechnology firm focused on discovering and developing minimally-toxic therapies to treat cancers, particularly those that affect the growing global geriatric population. The company was acquired by Cephalon, Inc. in May, 2005.

Satori Pharmaceuticals, Inc., located in Cambridge, MA is an emerging biopharmaceutical company developing a novel treatment for Alzheimer's disease.

Sequel Pharmaceuticals is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing novel, clinical-stage drug candidates.

Signal was established to develop a new generation of small molecule pharmaceuticals based on recent discoveries about the way genes are regulated. The company's products used gene control — essentially turning genes on and off — to treat inflammatory diseases, viral infections, and neurobiological disorders. The company was acquired by Celgene in September 2000.

Transcept Pharmaceuticals is a specialty pharmaceutical company in Corte Madera, CA developing products that utilize the company's proprietary drug delivery system. The Transcept system enhances the absorption of drug active agents, reduces first-pass drug inactivation by the liver, and decreases the time required for the onset of drug action, potentially to a level approaching that of parenteral administration. The company's lead product is for the treatment of sleep disorders.

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of life-threatening infections. The company's lead product candidate, TR-701 is a novel oral and IV oxazolidinone antibiotic with potent activity against Gram positive bacterial pathogens. Trius' pipeline includes three additional structure-based drug design programs directed at novel antibacterial targets.

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing novel small molecule therapies based on the genetic causes of select metabolic, neurological and cardiovascular diseases. Xenons products include XEN401 (pain) and XEN501 (cardiac arrhythmia), both of which are in IND-enabling pre-clinical development. Certain rights to XEN401 in select Asian countries have been exclusively licensed to Takeda. In addition, Xenon has other discovery stage programs focused on disorders of iron overload, atherosclerosis, and metabolic disorders. They also have ongoing collaborations with Roche Pharmaceuticals and Novartis Pharmaceuticals. Xenon is headquartered in Burnaby, British Columbia.

Cellomics was founded in 1996 to improve the efficiency of the drug discovery process with drug screening equipment using fluorescence cell-based assays. The company's technology provided an unprecedented depth of information about a drug candidate's impact on specific targets within living cells before initiating animal testing or clinical trials.

Cellomics was founded in 1996 to improve the efficiency of the drug discovery process with drug screening equipment using fluorescence cell-based assays. The company's technology provided an unprecedented depth of information about a drug candidate's impact on specific targets within living cells before initiating animal testing or clinical trials.

Fluidigm Corporation develops and distributes systems based on the unique properties of integrated fluidic circuits (IFCs) to precisely control fluids on a nanovolume scale. The Company's vision is to create and to lead a new industry in which IFCs bring unparalleled efficiencies to the life science and allied fields. Fluidigm is based in South San Francisco, California.

AeroGen was founded in 1994 to pursue opportunities in aerosol drug delivery. AeroGen introduced a proprietary piezo-electric inhalation mechanism that was suitable for use with small-molecule pharmaceuticals and large-molecule therapeutics and targeted specific regions of the lung and various dosages.

AeroGen was founded in 1994 to pursue opportunities in aerosol drug delivery. AeroGen introduced a proprietary piezo-electric inhalation mechanism that was suitable for use with small-molecule pharmaceuticals and large-molecule therapeutics and targeted specific regions of the lung and various dosages.

Founded in July 2001, Archus Orthopedics is a privately held company developing a family of reconstructive implants to treat a variety of spine disorders resulting from degenerative changes in the facet joints. In January 2006, the company announced completion of a $35 Million financing led by Johnson & Johnson Development Corporation in cooperation with DePuy Spine.

Founded in 1993, ArthroCare Corp. is a medical device company that develops, manufactures and markets minimally invasive surgical products based on its patented Coblation technology, which uses low-temperature radiofrequency energy to gently and precisely dissolve rather than burn soft tissue — minimizing damage to healthy tissue.

Calypso Medical Technologies is a revenue-stage medical device company developing real-time localization technology for the precise tracking of tumor targets in radiation therapy. Calypso is located in Seattle, WA.

Carbylan BioSurgery develops and markets bioresponsive medical products to enhance healing, provide better surgical outcomes and improve patients' quality of life. Carbylan is committed to quality in all areas of its business by complying with regulatory requirements and improving the effectiveness of its quality system.

Cardiac Dimensions Inc. is based in Kirkland, WA, and develops and manufactures percutaneous devices designed for treating mitral valve regurgitation in patients with congestive heart failure. Cardiac Dimensions has demonstrated proof-of-concept in animal studies and is conducting human feasibility studies with its device.

CVRx located in Maple Grove, MN, has developed an implantable device for the treatment of hypertension, or high blood pressure, in patients who cannot control their blood pressure with medications and lifestyle modifications. The company received FDA approval for an investigational device exemption (IDE) to begin a pivotal clinical trial to evaluate the safety and effectiveness of its RheosTM Baroreflex Hypertension TherapyTM System. The device has had early clinical success in European and U.S. feasibility clinical trials, and has demonstrated it can significantly reduce blood pressure in patients with drug- resistant hypertension. CVRx is private company and its senior management and technical teams have many years of experience commercializing implantable medical devices.

Cygnus Research was founded to design, develop, and manufacture transdermal drug delivery and diagnostic systems incorporating unique polymer and adhesive formulations. The company was sold in May 1991 to Ortho-McNeil Pharmaceutical, a Johnson & Johnson Company.

Devax, a private emerging medical device company located in Irvine, California, is engaged in the development of a proprietary, drug-eluting bifurcated stent system, the AXXESS PLUS, that provides a clinical solution to treat atherosclerotic disease in coronary bifurcation lesions. Devax is currently conducting a pivotal clinical trial in support of FDA approval.

Epicor Medical was founded in 1999 to develop new devices and procedures for the treatment of atrial fibrillation using high-intensity focused ultrasound. Epicor Medical's innovative approach to treating atrial fibrillation stands to cure patients, while minimizing complications associated with most invasive treatments available today. St. Jude Medical acquired the company in June, 2004.

Follica, Inc. is developing novel therapies for conditions and disorders of the hair follicle, the epicenter for the development and replenishment of human hair and skin.

Glaukos Corporation is focused on treating glaucoma, a common and potentially blinding eye disease characterized by elevated pressure inside the eye. The Glaukos devices are tiny titanium tubes which are implanted inside the eye via a minimally invasive procedure that increases fluid outflow from the eye. The promise of the technology is that it could be a definitive solution for glaucoma and eliminate the need for most medications.

Gynesonics is developing a minimally invasive, uterine-sparing treatment for fibroid tumors. It is an ultrasound-guided needle ablation device designed for in-office use by the gynecologist.

Gynesonics is developing a minimally invasive, uterine-sparing treatment for fibroid tumors. It is an ultrasound-guided needle ablation device designed for in-office use by the gynecologist.

The mission of Integrated Diagnostics is to leverage powerful emerging technologies in the development of diagnostic products that enable physicians and patients to manage complex and important diseases such as cancer, diabetes and Alzheimer's through blood tests that can monitor tens to hundreds of disease markers simultaneously. The company plans to develop a pipeline of game-changing diagnostic products that enable the diagnosis and prognosis of a variety of diseases. The company is based on the concept of a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules.

Based in St. Paul, Minnesota, Integ was dedicated to the development of the LifeGuide system and other new glucose monitoring technology to make testing easier for the 100 million people worldwide who have diabetes. Integ was acquired by Inverness Medical in October, 2000 and subsequently acquired by Johnson & Johnson in June, 2001.

Invuity was founded in 2004 by an orthopedic surgeon and an optical engineer with the goal of improving visualization in less invasive surgery. Located in San Francisco, Invuity has assembled an organization of world class engineers, surgeons and physicists to pioneer new technology for advanced visualization solutions.

IVT was founded in 1983 to develop new technologies and devices for use in the field of intravascular intervention in arteriosclerotic disease. The company introduced tools for use in vascular microsurgery as well as in traditional balloon dilatation intervention. The company was acquired by Boston Scientific in February, 2001.

IntraLase has developed a revolutionary all-laser surgical technology with IntraLase has developed a revolutionary all-laser surgical technology with multiple uses in ophthalmology and other medical areas. The lead application - making precise surgical flaps for laser vision correction procedures - has enormous commercial potential in the field of refractive surgery. IntraLase completed an initial public offering in October, 2004 and was acquired by AMO in January, 2007.

LenSx Lasers is developing a next generation femtosecond laser that can operate inside the eye to make cataract surgery safer and more effective. The founding team is the founding team from IntraLase (ILSE), a highly successful InterWest company manufacturing lasers for LASIK, and that was acquired by AMO in 2007 for $808M.

Menlo Care was a company with materials, science, and manufacturing know-how transferred from Raychem Corporation, started in 1985 to develop "low trauma," high-performance catheters that are less harmful to patients' veins and can be left in place for longer periods of time. Menlo Care was acquired by Johnson & Johnson in May, 1995.

MicroCHIPS, Inc. is pioneering intelligent implanted devices designed to improve the health of millions of people with chronic conditions that require careful monitoring and precise therapy.

Based on proprietary microreservoir technology first developed at the Massachusetts Institute of Technology, MicroCHIPS' platform incorporates long-term implant technologies and wireless communications, as well as expertise in protein and peptide formulation for challenging delivery conditions. MicroCHIPS' technologies are designed to transform electromechanical medical devices into highly tuned biochemical sensing and therapy systems.

Microfabrica, Inc., located in Van Nuys, CA, is a developer of micro- and millimeter-scale devices and systems used in a large variety of medical device, electronics and defense applications.

Nanogen's advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip(R) 400 electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications.

Neuronetics, Inc. is a privately held medical device company focused on developing therapies for psychiatric and neurological disorders using electromagnetic energy. Based in Malvern, PA., Neuronetics is the leader in the development of transcranial magnetic stimulation, a completely non-invasive form of neuromodulation.

NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders by responsive brain stimulation. The company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide. Patients are currently being enrolled in a clinical trial of the company's Responsive Neurostimulator (RNS(TM)) system for treating medically refractory epilepsy.In addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.Located in Mountain View, California, NeuroPace is a privately-held company with approximately 70 employees.

Ophthonix, Inc., a San Diego based, venture-funded ophthalmic company, is manufacturing and marketing exceptional vision assessment and correction technologies to greatly enhance vision quality. Ophthonix is currently advancing a system that will improve the ability of eye care practitioners to care for their patients and benefit the millions around the world requiring vision correction.

Paracor Medical, Inc. is a medical company creating a novel, minimally-invasive device to transform the treatment and prevention of Congestive Heart Failure (CHF). The HeartNet is a ventricular support mesh that reduces heart wall stress to aid in ventricular function. Paracor Medical is conducting a clinical feasibility trial with the device.

PercuSurge pioneered a new market segment in interventional cardiology products with a series of balloon catheters designed to trap and remove the potentially harmful debris that breaks loose during balloon angioplasty and stent placement procedures. The company was acquired by Medtronic in December, 2000.

PrimeraDx's patented STAR technology represents the next generation in real-time PCR offering both quantification and true multiplexing up to 60 analytes in a single sample, enabling multiple results in the same time and costs of a single assay. Their technology will deliver more information to the physician, reduce costs for the lab and enhances patient care by increasing the chances of early detection of disease.

Radiant Medical is developing minimally invasive catheter-based devices which produce regional body cooling for the treatment of stroke and other nuerological diseases.

ReVision Optics is developing an intracorneal optical implant for surgical vision correction of presbyopia.

Restoration Robotics is an aesthetics company developing a robotic device to provide increased speed and precision in hair transplantation. The office-based device is capable of rapidly harvesting and implanting individual hairs minimally invasively, automating the tedious manual surgical technique now being performed by hair transplant surgeons.

Spinal Dynamics was a medical device company which developed one of the leading artificial disk implants, Aeto, in order to replace natural intervertebral disks damaged by degenerative joint disease. The company was acquired by Medtronic in October 2002.

Spiration designs and manufactures innovative thoracic and intra-bronchial medical devices for the treatment of lung disease, including chornic obstructive pulmonary disease (COPD), specifically emphysema.

TheraSense was a medical device company in Alameda, CA developing two new product lines to dramatically change the way people with diabetes test and monitor their glucose levels. TheraSense was acquired by Abbott Laboratories in April, 2004.

Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide.

USGI Medical is a privately held, medical device company in San Clemente, CA focused on the development of technologies to enable advanced therapeutic procedures to be preformed through the natural passageways of the GI tract.

Ventana Medical Systems develops, manufactures, and markets instrument/reagent systems that automate slide preparation and staining in anatomical pathology and drug discovery laboratories worldwide. Ventana is headquartered in Tucson, AZ.

Ventritex established itself in the 1980s as a leading maker of implantable defibrillators, surgically implanted devices that automatically correct potentially lethal abnormal heart rhythms known as cardiac arrhythmias. Ventritex completed an initial public offering in January, 1993, and was acquired by St. Jude Medical in May, 1997.

InterWest invested in this company in 1993, when it refocused its business on a "hospital-within-hospital" model for providing subacute transitional health care services for long-term patients with a tailored mix of services to maximize outcome. ATH was acquired by Beverly (NYSE: BEV) in 1994.

InterWest invested in this company in 1993, when it refocused its business on a "hospital-within-hospital" model for providing subacute transitional health care services for long-term patients with a tailored mix of services to maximize outcome. ATH was acquired by Beverly (NYSE: BEV) in 1994.

HMA owns or leases several hospitals and manages others. The company started with a strategy of buying or leasing small to medium-size proprietary hospitals, primarily in the southeastern and southern U.S.

This site management organization conducts clinical trials at a consortium of leading investigator sites for pharmaceutical and biotech companies developing drugs and devices for the treatment of central nervous system disorders, including chronic pain.

Medaphis provides a variety of financial services for the health care market, from receivables management and collections to electronic insurance claims submission, as well as office management services for group practices.

At its founding, Paradigm was the first specialty managed care company to provide comprehensive medical and risk management services on a turnkey basis, specializing in sophisticated case management of catastrophic workers' compensation cases, particularly those involving brain or spinal injuries.

Presidium is a health care service company focused on the workers' compensation and disability marketplace. It offers a complete set of claims management and managed care services that allow self-insured, mid-sized companies to manage their workers' comp and short-term disability claims cost-effectively and with good outcomes.

Quantum established itself as a provider of mail order and in-the-home services and support to hemophiliacs and their families, then extended the its business and service model to those afflicted by other chronic genetic disorders such as cystic fibrosis, sickle cell anemia, Crohn's disease, and alpha-1 anti-trypain deficiency.

TheraTx provides rehabilitative services — physical therapy, occupational therapy, and speech therapy — to skilled nursing facilities, which are called now upon to provide more and more subacute care and rehabilitation to patients in transition from hospitals to home.

Healthcentral is one of the leading consumer healthcare information websites, centered on the exclusive content provided by Dr. Dean Edell, a nationally syndicated medical commentator and writer.

Healthcentral is one of the leading consumer healthcare information websites, centered on the exclusive content provided by Dr. Dean Edell, a nationally syndicated medical commentator and writer.